Publication: Successful treatment of normocomplementemic urticarial vasculitis with omalizumab: A report of three cases and literature review
Issued Date
2020-12-01
Resource Type
ISSN
0125877X
Other identifier(s)
2-s2.0-85098165389
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Pacific journal of allergy and immunology. Vol.38, No.4 (2020), 286-289
Suggested Citation
Teerapong Rattananukrom, Pranee Svetvilas, Kumutnart Chanprapaph Successful treatment of normocomplementemic urticarial vasculitis with omalizumab: A report of three cases and literature review. Asian Pacific journal of allergy and immunology. Vol.38, No.4 (2020), 286-289. doi:10.12932/AP-050918-0402 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/60935
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Successful treatment of normocomplementemic urticarial vasculitis with omalizumab: A report of three cases and literature review
Other Contributor(s)
Abstract
Urticarial vasculitis (UV) is a rare form of cutaneous leukocytoclastic vasculitis with persistent urticarial lesions. UV may be severe and refractory to standard treatment including antihistamines, anti-inflammatories, antimalarials, corticosteroids and immunosuppressants. Omalizumab, an anti-IgE antibody, is approved for chronic spontaneous urticaria. However, its benefit for UV remains controversial. We report, herein, three patients with normocomplementemic UV and angioedema. All patients were diagnosed with chronic urticaria preceding the presentation of painful urticarial plaques. The diagnosis of UV was confirmed by skin biopsy and/or direct immunofluorescence. All patients had none or minimal response to standard treatments. Initial omalizumab dosing of 150 mg was administered subcutaneously (SC), however, increment to 300 mg monthly was necessary in 2 patients to control the disease. All 3 patients remained in complete remission after minimum follow up period of 9 months. To conclude, omalizumab has shown to be beneficial for severe normocomplementemic UV in our series.